| Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. | |
| | |
MedLine Citation:
|
PMID: 16908351 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Rituximab is an anti-CD20 chimeric antibody that selectively targets B lymphocytes. Recently, it has been reported to be beneficial in treating pemphigus vulgaris. OBJECTIVE: Our aim was to review the English-language literature on the treatment of pemphigus vulgaris (PV) with rituximab and to determine its efficacy and influence on clinical outcome(s). MATERIAL AND METHODS: A retrospective review of the literature on the use of rituximab in the treatment of PV was conducted. Seventeen patients in 10 reports were described and their data were reviewed. RESULTS: The majority of patients received one course of rituximab along with conventional immunosuppressive therapy as concomitant therapy; 88% of the patients demonstrated improvement. More than half of the patients were followed up for more than 6 months after rituximab treatment; they appeared to be clinically disease free, but were still receiving conventional immunosuppressive therapy. Side effects in most patients were transient and infusion related. Serious infections occurred in 4 patients. One patient died. LIMITATIONS: The sample size of this study is small; there is no uniformity of data collection or measurement of key and critical indices, and follow-up was limited. CONCLUSION: Rituximab may be a promising agent in treatment of PV. |
| | |
Authors:
|
Abdul Kader El Tal; Marshall R Posner; Zachary Spigelman; A Razzaque Ahmed |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of the American Academy of Dermatology Volume: 55 ISSN: 1097-6787 ISO Abbreviation: J. Am. Acad. Dermatol. Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-08-15 Completed Date: 2006-09-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7907132 Medline TA: J Am Acad Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 449-59 Citation Subset: IM |
Affiliation:
|
Department of Medicine, New England Baptist Hospital, Harvard School of Dental Medicine, Boston, Massachusetts 02120, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies
/
blood Antibodies, Monoclonal / immunology, therapeutic use* Antigens, CD20 / immunology* B-Lymphocytes / pathology Humans Immunologic Factors / therapeutic use* Lymphocyte Count Pemphigus / drug therapy*, immunology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies; 0/Antibodies, Monoclonal; 0/Antigens, CD20; 0/Immunologic Factors; 0/rituximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort s...
Next Document: Is melanocytic nevus with focal atypical epithelioid components (clonal nevus) a superficial variant...